Status:
COMPLETED
Biomarkers and Epigenetic Markers Associated With Pain in Patients With Symptomatic Atrial Fibrillation
Lead Sponsor:
Region Örebro County
Collaborating Sponsors:
Aalborg University
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
20-75 years
Brief Summary
Atrial fibrillation (AF) is the most common sustained arrhythmia and the number of patients with AF is expected to increase substantially in the coming decades. One third of patients with AF report no...
Eligibility Criteria
Inclusion
- On waiting list for AF ablation (only symptomatic subjects are offered ablation)
- Paroxysmal AF and persistent AF (AF that is continuously sustained beyond 7 days, including episodes terminated by cardioversion after ≥7 days)
- Written informed consent
Exclusion
- Previous pulmonary vein isolation
- Cognitive or psychiatric condition
- Diabetes mellitus
- Ischemic heart disease
- Heart failure
- Asthma
- Pregnancy
- Previous/current drug or alcohol abuse
- Previous neurological or concomitant musculoskeletal disorders
- Continuous analgesic medication
Key Trial Info
Start Date :
January 10 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 10 2023
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT05201989
Start Date
January 10 2022
End Date
December 10 2023
Last Update
April 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of cardiology
Örebro, Sweden, 70185